Published in Medical Letter on the CDC and FDA, March 13th, 2005
In response to the committee's encouragement that new technologies should be considered that might lead to greater reduction of risk while not deferring many donors unnecessarily, Pall Corporation (NYSE:PLL) presented the latest scientific data on its new prion reduction technology. The Leukotrap Affinity Prion Reduction Filter, expected to be launched commercially in Europe...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.